You are here: Industry Insights > ulcerative colitis

News List

Bristol Myers Squibb Receives European Commission Approval of Zeposia for Ulcerative Colitis AmericanPharmaceuticalReview
December 01, 2021
Bristol Myers Squibb today announced that the European Commission has granted a Marketing Authorization for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response...
Six Proteins Upregulated Years Before Ulcerative Colitis Diagnosis Drugs
November 25, 2021
Six inflammatory proteins are upregulated in plasma several years before diagnosis of ulcerative colitis, according to a report published in the November issue of Gastroenterology.
Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis drugs
August 24, 2021
Theravance Biopharma, Inc. today announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis.
Seres’ ulcerative colitis candidate misses primary endpoint in mid-stage study pharmatimes
July 26, 2021
Microbiome therapeutics company Seres Therapeutics has announced that a Phase IIb study of its potential ulcerative colitis (UC) candidate SER-287 failed to meet its primary endpoint.
Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study drugs
July 16, 2021
Eli Lilly and Company (NYSE: LLY) announced new Phase 2 data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction treatment were maintained for up to one year.
Galapagos’ filgotinib leads to rapid symptom improvement for ulcerative colitis patients pharmatimes
July 13, 2021
A post-hoc analysis from a Phase III clinical programme evaluating Galapagos’ filgotinib showed significant symptom improvements for patients with ulcerative colitis (UC).
Rinvoq scores positive results as a maintenance therapy for ulcerative colitis pharmatimes
July 02, 2021
AbbVie’s JAK inhibitor Rinvoq met the primary and all secondary endpoints in a Phase III ulcerative colitis maintenance study, the company announced earlier this week.
Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis prnasia
June 15, 2021
Bridge Biotherapeutics (KQ288330) announced the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle (PoCP) study to examine the drug's efficacy and safety in active ulcerative colitis (NCT04596293).
Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site prnasia
June 02, 2021
Bridge Biotherapeutics today announced the first patient dosing of BBT-401 in its open label, proof of mechanism study to examine the drug's efficacy and safety in active ulcerative colitis when delivered rectally to the colon (NCT04478825).
U.S. FDA Approves an Oral Treatment for Adults with Ulcerative Colitis americanpharmaceuticalreview
June 02, 2021
Bristol Myers Squibb announced that the U.S. FDA approved Zeposia® (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).

Previous page 1 2 3 4 5 Next page